Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market Opportunity
Rhea-AI Impact
(High)
Rhea-AI Sentiment
(Neutral)
Tags
Key Terms
uveitismedical
Uveitis is inflammation inside the eye that can damage tissues responsible for clear vision, causing pain, light sensitivity, blurred sight, or permanent vision loss if untreated. For investors, it matters because it represents a medical condition with significant unmet need and chronic treatment requirements, influencing the size of potential drug or device markets, clinical trial design and endpoints, regulatory hurdles, and long-term revenue prospects — similar to how chronic engine trouble signals ongoing repair and maintenance demand.
topical steroidsmedical
Topical steroids are medicines applied directly to the skin that reduce inflammation, redness and itching by calming the immune response—think of them as a fire extinguisher for flare-ups such as eczema or psoriasis. They matter to investors because their safety profile, approved uses, strength classes and patent/generic status drive product sales, regulatory scrutiny and liability risk; changes in any of these factors can affect revenues and valuation for companies in dermatology and pharmaceuticals.
cataractmedical
A cataract is a clouding of the eye’s natural lens that blurs vision, like looking through a fogged camera lens; it develops gradually and can lead to reduced ability to read, drive, or recognize faces. Investors care because cataracts drive demand for surgeries, implants, drugs and diagnostic tools, influence healthcare spending and reimbursement decisions, and affect the commercial prospects and regulatory pathways of companies that develop treatments or devices.
glaucomamedical
Glaucoma is a group of eye diseases that slowly damage the optic nerve, often because fluid buildup raises pressure inside the eye, and can lead to permanent vision loss if untreated. For investors, glaucoma matters because it creates sustained demand for medications, surgical devices, diagnostics and follow-up care; breakthroughs or approvals can drive sales and market value much like fixing a clogged drain prevents damage to a house’s wiring.
lymphocytemedical
A lymphocyte is a type of white blood cell that acts like a body's security guard, identifying and helping remove infections, abnormal cells, or foreign substances. For investors, lymphocyte counts matter because they are common safety and efficacy measures in clinical trials and ongoing drug monitoring: changes can signal immune effects, side effects, or therapeutic activity that influence regulatory decisions, trial outcomes, and a treatment's market prospects.
anterior chambermedical
The anterior chamber is the front, fluid-filled space inside the eye between the clear outer window (cornea) and the colored part (iris); think of it like the small reservoir in front of a camera lens. It matters to investors because many eye drugs, surgical devices and safety tests target or affect this space—changes in its pressure, fluid balance or clarity can determine a treatment’s effectiveness, side effects and regulatory approval.
malignant fungating woundsmedical
Malignant fungating wounds are open, often damaged patches of skin and tissue that develop when an advancing cancer breaks through the skin, leading to pain, odor, bleeding and high infection risk. Investors care because these wounds drive demand for specialized wound-care products, palliative drugs, medical devices and home care services; like a house with a chronic leak, they create ongoing treatment costs, regulatory scrutiny and potential market opportunity for better therapies.
VT-1908 was demonstrated to be effective as a topical steroid in the uveitis preclinical model and shows very good safety
Plans to generate human clinical data using the India innovation corridor in a very cost-efficient manner
No change in capital deployment plan; laser focused on our lead program, VT-1953 (for treatment of malodor of MFW), Phase 3 study
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Vyome Holdings, Inc. (“Vyome”) (Nasdaq: HIND) announced the publication of its preclinical data validating the efficacy and safety of VT-1908 as a potential treatment for uveitis in the peer-reviewed Journal of Ophthalmic Inflammation and Infection, a Springer-Nature journal1.
Uveitis refers to the immune-inflammation of the eye, and accounts for 10–15% of all cases of blindness in the developed world2. In the United States alone, it is associated with an estimated 30,0003 new cases of legal blindness annually, and represents an estimated $3 billion market opportunity by 20324. Topical steroids are the standard first line of treatment for uveitis. However, many patients experience inadequate response, and prolonged steroid use is associated with major complications, including cataract formation and increased pressure in the eye, leading to glaucoma.
In this publication1, topical eye drops of VT-1908 resulted in the desired concentration of the active drug being achieved in the eye without any irritation or signs of toxicity. VT-1908-treated eyes showed a significant reduction (p < 0.0010) in the uveitis score with reduced lymphocyte counts in the anterior chamber compared to vehicle control. VT-1908 was found to be as effective as topical prednisone (steroid) in the preclinical model.
“There remains a significant unmet need for safe and effective topically administered therapies to replace topical steroid use in the treatment of ocular inflammation. While steroids are widely used, they are associated with well-documented complications. The fact that VT-1908 was as effective as a steroid in the uveitis preclinical model and shows a very good safety profile supports its potential as an effective alternative to steroids in the eye,” said Shiladitya Sengupta, Associate Professor of Medicine at Harvard Medical School and Co-founder of Vyome.
”The publication of this paper in the peer-reviewed Springer-Nature journal underscores the scientific rigor underlying Vyome’s approach to addressing inflammation in the eye. The broader addressable global market to treat inflammation in the eye is expected to exceed $20B by 20305,” said Venkat Nelabhotla, CEO of Vyome. “Based on our pre-clinical findings, we intend to leverage the India innovation corridor to advance VT-1908 into clinical development in a very capital-efficient manner, to generate human clinical data that could result in a significant value inflection.”
With no change in the capital use plan, Vyome continues to be laser-focused on the Phase 3 study of lead program, VT-1953, which is being developed for the treatment of malodor of malignant fungating wounds (MFW), a condition representing an estimated $2.2 billion6 addressable market opportunity in the US alone, according to independent analyst Destum Partners.
Vyome is building the world’s premier platform spanning the US-India innovation corridor. Based in Cambridge, MA, Vyome’s immediate focus is on leveraging its clinical-stage assets to transform the lives of patients with immuno-inflammatory conditions. By applying groundbreaking science and its unique positioning across the US-India innovation corridor, Vyome seeks to deliver lasting value to shareholders in a hyper cost-efficient manner while upholding global standards of quality and safety. To learn more, please visit www.vyometx.com
Forward-Looking Statements
Certain statements made in this press release are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “target,” “believe,” “expect,” “will,” “shall,” “may,” “anticipate,” “estimate,” “would,” “positioned,” “future,” “forecast,” “intend,” “plan,” “project,” “outlook,” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such statements include, but are not limited to, statements contained in this press release relating to Vyome’s business strategy, Vyome’s future operating results and liquidity and capital resources outlook. Forward-looking statements are based on Vyome’s current expectations and assumptions regarding Vyome’s business, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Vyome’s actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. Vyome cautions you therefore against relying on any of these forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, Vyome’s ability to leverage the India innovation corridor and otherwise advance VT-1908 into clinical development in a capital-efficient manner; Vyome’s ability to raise capital to fund continuing operations; our ability to protect Vyome’s intellectual property rights; the impact of any infringement actions or other litigation brought against Vyome; competition from other providers and products; Vyome’s ability to develop and commercialize products and services; changes in government regulation; Vyome’s ability to complete capital raising transactions; and other factors relating to Vyome’s industry, operations and results of operations. Actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned. Factors or events that could cause Vyome’s actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results, levels of activity, performance or achievements. Vyome’s assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release, except as may be required under applicable securities law.
